Iconovo AB (publ) (STO:ICO)

Market Cap	25.89M
Revenue (ttm)	22.00M
Net Income (ttm)	-42.76M
Shares Out	21.22M
EPS (ttm)	-2.40
PE Ratio	n/a
Forward PE	12.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,844
Average Volume	37,447
Open	1.245
Previous Close	1.220
Day's Range	1.195 - 1.285
52-Week Range	1.050 - 12.250
Beta	0.69
RSI	20.08
Earnings Date	Apr 25, 2025

About Iconovo AB

Iconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has collaboration agreement with Affilogic, ENA Respiratory Pty Ltd, Lonza, and Stevanato Group, as well as licensing agreements with Kiox Pharma and Monash Uni...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2013
• Employees: 29
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ICO

Financial Performance

In 2024, Iconovo AB's revenue was 24.00 million, a decrease of -14.63% compared to the previous year's 28.11 million. Losses were -41.14 million, -10.36% less than in 2023.